Soligenix (NASDAQ:SNGX) Announces Earnings Results

Soligenix (NASDAQ:SNGX) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.04, Zacks reports.

Soligenix Stock Performance

Shares of Soligenix stock traded up $0.01 on Friday, hitting $0.39. The company’s stock had a trading volume of 130,758 shares, compared to its average volume of 304,500. Soligenix has a 1 year low of $0.28 and a 1 year high of $6.23. The firm has a fifty day moving average price of $0.41 and a 200-day moving average price of $0.81. The company has a market capitalization of $5.81 million, a price-to-earnings ratio of -0.23 and a beta of 1.93.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Soligenix has a consensus rating of “Sell”.

Hedge Funds Weigh In On Soligenix

A number of hedge funds have recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in shares of Soligenix in the fourth quarter valued at approximately $37,000. StoneX Group Inc. acquired a new position in Soligenix during the fourth quarter worth $50,000. Jane Street Group LLC acquired a new stake in shares of Soligenix in the fourth quarter valued at about $51,000. Banco BTG Pactual S.A. purchased a new stake in shares of Soligenix during the third quarter worth about $54,000. Finally, Virtu Financial LLC acquired a new position in shares of Soligenix during the 3rd quarter worth about $59,000. Hedge funds and other institutional investors own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.